210 related articles for article (PubMed ID: 11060661)
1. Ascomycins: promising agents for the treatment of inflammatory skin diseases.
Paul C; Graeber M; Stuetz A
Expert Opin Investig Drugs; 2000 Jan; 9(1):69-77. PubMed ID: 11060661
[TBL] [Abstract][Full Text] [Related]
2. Ascomycins in dermatology.
Paul C; Ho VC
Semin Cutan Med Surg; 1998 Dec; 17(4):256-9. PubMed ID: 9859912
[TBL] [Abstract][Full Text] [Related]
3. Pimecrolimus: a review.
Gupta AK; Chow M
J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
[TBL] [Abstract][Full Text] [Related]
4. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.
Grassberger M; Baumruker T; Enz A; Hiestand P; Hultsch T; Kalthoff F; Schuler W; Schulz M; Werner FJ; Winiski A; Wolff B; Zenke G
Br J Dermatol; 1999 Aug; 141(2):264-73. PubMed ID: 10468798
[TBL] [Abstract][Full Text] [Related]
5. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG
Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539
[TBL] [Abstract][Full Text] [Related]
6. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
Luger T; Van Leent EJ; Graeber M; Hedgecock S; Thurston M; Kandra A; Berth-Jones J; Bjerke J; Christophers E; Knop J; Knulst AC; Morren M; Morris A; Reitamo S; Roed-Petersen J; Schoepf E; Thestrup-Pedersen K; Van Der Valk PG; Bos JD
Br J Dermatol; 2001 Apr; 144(4):788-94. PubMed ID: 11298538
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.
Van Leent EJ; Gräber M; Thurston M; Wagenaar A; Spuls PI; Bos JD
Arch Dermatol; 1998 Jul; 134(7):805-9. PubMed ID: 9681343
[TBL] [Abstract][Full Text] [Related]
8. First experience of topical SDZ ASM 981 in children with atopic dermatitis.
Harper J; Green A; Scott G; Gruendl E; Dorobek B; Cardno M; Burtin P
Br J Dermatol; 2001 Apr; 144(4):781-7. PubMed ID: 11298537
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus--a safe and effective local immunomodulator in the treatment of inflammatory skin diseases.
Lipozencić J
Acta Dermatovenerol Croat; 2005; 13(1):63-9. PubMed ID: 15788149
[TBL] [Abstract][Full Text] [Related]
10. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981.
Neckermann G; Bavandi A; Meingassner JG
Br J Dermatol; 2000 Apr; 142(4):669-79. PubMed ID: 10792216
[TBL] [Abstract][Full Text] [Related]
11. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.
Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP
Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007
[TBL] [Abstract][Full Text] [Related]
12. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology.
Meingassner JG; Grassberger M; Fahrngruber H; Moore HD; Schuurman H; Stütz A
Br J Dermatol; 1997 Oct; 137(4):568-76. PubMed ID: 9390333
[TBL] [Abstract][Full Text] [Related]
13. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.
Mollison KW; Fey TA; Gauvin DM; Kolano RM; Sheets MP; Smith ML; Pong M; Nikolaidis NM; Lane BC; Trevillyan JM; Cannon J; Marsh K; Carter GW; Or YS; Chen YW; Hsieh GC; Luly JR
J Invest Dermatol; 1999 May; 112(5):729-38. PubMed ID: 10233764
[TBL] [Abstract][Full Text] [Related]
14. Pimecrolimus for the treatment of inflammatory skin disease.
Wolff K; Stuetz A
Expert Opin Pharmacother; 2004 Mar; 5(3):643-55. PubMed ID: 15013932
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases.
Bornhövd EC; Burgdorf WH; Wollenberg A
Curr Opin Investig Drugs; 2002 May; 3(5):708-12. PubMed ID: 12090543
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
17. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion.
Mrowietz U; Graeber M; Bräutigam M; Thurston M; Wagenaar A; Weidinger G; Christophers E
Br J Dermatol; 1998 Dec; 139(6):992-6. PubMed ID: 9990361
[TBL] [Abstract][Full Text] [Related]
18. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
19. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.
Mollison KW; Fey TA; Gauvin DM; Sheets MP; Smith ML; Pong M; Krause R; Miller L; Or YS; Kawai M; Wagner R; Wiedeman PE; Clark RF; Gunawardana IW; Rhoades TA; Henry CL; Tu NP; BaMaung NY; Kopecka H; Liu L; Xie Q; Lane BC; Trevillyan JM; Marsh K; Luly JR
Curr Pharm Des; 1998 Oct; 4(5):367-79. PubMed ID: 10197049
[TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
Wolff K
Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
